

Freedom of Information Request	FOI 22-005	8 th April 2022
--------------------------------	------------	----------------------------

Q1. In the last 6 months, how many patients has your trust treated (for any condition) with the following treatments

The Health Board is unable to provide information on the number of patients treated with specific drugs. However, please find below the quantities dispensed, across Health Board pharmacies for the period October 2021 – March 2022:

- **Avatrombopag**
AVATROMBOPAG 20 mg Tablets 10 Tablet Pack x 9
- **Eltrombopag**
ELTROMBOPAG 25 mg Tablets 28 Tablet Pack x 32
ELTROMBOPAG 50 mg Tablets 28 Tablet Pack x 31
- **Fostamatinib**
- **Romiplostim**
ROMIPLOSTIM 125 micrograms Subcutaneous Injection 1 Vial Pack x 96
ROMIPLOSTIM 250 micrograms Subcutaneous Injection 1 Vial Pack x 378

Q2. In the last 6 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3)?

For the period 1st August 2021 and 31st January 2022

49 patients treated were treated as inpatients, day cases or regular day attenders for immune thrombocytopenia (ICD10 code D69.3)

Q3. In the last 6 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:

- **Avatrombopag** - 0
- **Mycophenolate mofetil** - 0
- **Rituximab** - 5
- **Surgery (splenectomy)** - 0

Q4. Does your trust participate in any clinical trials for the treatment of Immune thrombocytopenia? If so, can you please provide the name of each trial and the number of patients taking part.

The Health Board is not running any clinical trials for the treatment of Immune thrombocytopenia.